SEARCH
検索詳細
中谷 彰洋 (ナカヤ アキヒロ)
| 薬学研究院 医療薬学部門 ナノ医薬品創剤学分野（寄附分野） | 特任助教 |
研究活動情報
■ 論文- CPP–PEG‐Guided Surface Engineering of Mitochondria Enables Efficient Cellular Uptake and Respiratory Modulation
Masahiro Shiraishi; Yukari Muramatsu; Akihiro Nakaya; Yuji Maruo; Rick C. Tsai; Masashi Suganuma; Hisashi Ohta; Atsuhito Takeda; Hideyoshi Harashima; Yuma Yamada
Advanced Materials Interfaces, Wiley, 2026年07月01日, ［査読有り］
英語, 研究論文（学術雑誌）, ABSTRACT
Mitochondrial transplantation has emerged as a promising strategy for modulating cellular bioenergetics in mitochondrial dysfunction. However, isolated mitochondria suffer from poor stability and limited cellular uptake, restricting their therapeutic application. To address these limitations, we developed a surface engineering strategy that stabilizes isolated mitochondria while enabling interactions with target cells, providing a platform for selective organ‐ and cell‐targeting. Polyethylene glycol (PEG) with lipid/carbon chains was introduced to mitochondria‐associated membrane structures, forming a protective hydration layer on the mitochondrial surface. This PEG layer also serves as a modular platform for functionalization with biomolecules, such as peptides and antibodies, thereby broadening its biomedical applications. In this study, we examined whether mitochondrial function in target cells can be modulated using PEG‐shielded mitochondria functionalized with a cell‐penetrating peptide (CPP) via a maleimide linkage. Our results suggest that CPP‐PEG‐modified mitochondria exhibit efficient cellular internalization and are associated with increased mitochondrial respiratory activity, consistent with intracellular bioenergetic modulation. These findings suggest that spatially controlled presentation of CPP at the terminus of a PEG layer may provide an effective approach for stabilizing isolated mitochondria while modulating intracellular dynamics and functional responses. This surface engineering strategy offers a proof‐of‐concept design framework for mitochondria‐associated engineering and future bioenergetic strategies. - Nanoparticulation of BCG-CWS for application to bladder cancer therapy
Takashi Nakamura; Masafumi Fukiage; Megumi Higuchi; Akihiro Nakaya; Ikuya Yano; Jun Miyazaki; Hiroyuki Nishiyama; Hideyuki Akaza; Toshihiro Ito; Hiroyuki Hosokawa; Toshinori Nakayama; Hideyoshi Harashima
Journal of Controlled Release, 176, 44, 53, Elsevier BV, 2014年02月, ［査読有り］
英語, 研究論文（学術雑誌） - The liposome incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette Guéin can directly enhance the susceptibility of cancer cells to lymphokine activated killer cells through up regulation of natural killer group 2 member D ligands
Jun Miyazaki; Koji Kawai; Takahiro Kojima; Takehiro Oikawa; Akira Joraku; Toru Shimazui; Akihiro Nakaya; Ikuya Yano; Takashi Nakamura; Hideyoshi Harashima; Hideyuki Akaza
BJU International, 108, 9, 1520, 1526, Wiley, 2011年02月11日, ［査読有り］
英語, 研究論文（学術雑誌）, OBJECTIVE
• To conduct a preclinical evaluation of the ability of natural killer cells to cytolyze bladder cancer cells that were modified to show enhanced expression of natural‐killer group 2, member D (NKG2D) ligands by R8‐liposome‐bacillus Calmette‐Guéin (BCG)‐cell wall skeleton (CWS) treatment.
MATERIALS AND METHODS
• The T24 cells and RT‐112 cells were co‐cultured with R8‐liposome‐BCG‐CWS and BCG for 2, 4, or 6 h, and then the surface expression of NKG2D ligands was analyzed using TaqMan real‐time quantitative RT‐PCR.
• Peripheral blood mononuclear cells were obtained with a conventional preparation kit, and then lymphokine‐activated killer (LAK) cells were generated from these purified peripheral blood mononuclear cells via interleukin‐2 stimulation.
• The anti‐tumour effect of LAK cells against untreated and R8‐liposome‐BCG‐CWS co‐cultured with cells of the human bladder cancer cell lines T24 and RT‐112 was analyzed using the cytotoxic WST‐8 assay method at 4 h of culture at various effector/target (E : T) ratios.
RESULTS
• Major histocompatibility complex class I‐related chain B (MICB) expression was increased ≈1.5‐fold on T24 cells and RT‐112 cells with BCG.
• UL‐16‐binding protein (ULBP) 1 expression was also increased ≈1.5‐fold on T24 cells and RT‐112 cells with BCG. R8‐liposome‐BCG‐CWS increased the surface expression of MICB 2.2‐fold on T24 cells but did not increase it significantly on RT‐112 cells.
• ULBP1 expression was increased ≈2.2‐fold on RT‐112 cells, although no differences were observed between the expression of ULBP2 and 3 with R8‐liposome‐BCG‐CWS.
• T24 cells that were co‐cultured with R8‐liposome‐BCG‐CWS showed an ≈1.3‐fold increase in sensitivity to cytolysis by LAK cells at an E : T ratio of 4 and RT‐112 cells showed an ≈1.4‐fold increase at an E : T ratio of 2.
CONCLUSIONS
• In the present study, the induction of surface NKG2D ligands by R8‐liposome‐BCG‐CWS rendered cancer cells more susceptible to cytolysis by LAK cells.
• T24 cells and RT‐112 cells, even when cultured singly in the absence of immune cells, can directly respond to R8‐liposome‐BCG‐CWS.
• The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against bladder cancers. - The Therapeutic Effects of R8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma
JUN MIYAZAKI; HIROYUKI NISHIYAMA; IKUYA YANO; AKIHIRO NAKAYA; HIDEYASU KOHAMA; KOJI KAWAI; AKIRA JORAKU; TAKASHI NAKAMURA; HIDEYOSHI HARASHIMA; HIDEYUKI AKAZA
Anticancer Research, 31, 2065, 2072, 2011年, ［査読有り］
研究論文（学術雑誌） - Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice
Kota Shigama; Akihiro Nakaya; Koji Wakame; Hiroshi Nishioka; Hajime Fujii
Journal of Experimental Therapeutics and Oncology, 8, 1, 43, 51, 2009年, ［査読有り］
英語, 研究論文（学術雑誌） - Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment activation
Ryouhei Tsutsumi; Kazuyuki Yokoyama; Yumiko Fujii; Susumu Ishikawa; Megumi Higuchi; Atsushi Takahashi; Yo Kurashima; Yasuhiro Teishikata; Shinya Tanaka; Takeshi Azuma; Masanori Hatakeyama
The Journal of Biological Chemistry, 279, 17, 17205, 17216, 2004年, ［査読有り］
英語, 研究論文（学術雑誌）
- BCG-CWS搭載ナノ粒子を基盤とした膀胱癌治療剤の開発
中村孝司; 吹上雅文; 中谷彰洋; 矢野郁也; 宮崎淳; 西山博之; 赤座英之; 伊藤俊宏; 細川裕之; 中山俊憲; 原島秀吉, 泌尿器外科, 27, 3, 338, 339, 2014年02月
日本語 - BCG-CWS搭載オクタアルギニンリポソーム製剤膀胱内注入によるBBN発癌ラットの治療効果について
宮崎淳; 河合弘二; 常楽晃; 中村孝司; 原島秀吉; 中谷彰洋; 小濱秀康; 矢野郁也; 赤座英之, 泌尿器外科, 23, 3, 304, 305, 2011年02月
日本語 - BCG cell wall skeleton内包リポソームベクターによるマウス膀胱癌治療モデル
常樂晃; 宮崎淳; 中谷彰洋; 中村孝司; 河合弘二; 矢野郁也; 原島秀吉; 赤座英之, 泌尿器外科, 23, 2, 184, 186, 2010年02月
日本語 - Helicobacter pylori病原因子CagAの生物活性決定要因としてのチロシンリン酸化サイトのバリエーション
中谷彰洋; 東秀明; 畠山昌則, Helicobacter Research, 7, 1, 25, 31, 2003年, ［筆頭著者］
日本語
- 天然型 BCG-CWS－B-OMS (JBL-107) の研究: 免疫療 法を標的としたB-OMSの新規アジュバントとしての免疫活性
松尾和浩; 中谷彰洋; 渋谷幸広; 中馬康志; 清原秀泰; 岸本修一; 福島昭二; 砂川 洵
第1２回次世代アジュバント研究会, 2019年01月22日, 英語, 口頭発表（一般）
2019年01月22日 - 2019年01月22日 - 天然型BCG-CWS: B-OMS (JBL-107)の研究 4. 免疫療法を標的とした、B-OMSの新規アジュバントとしての免疫活性
松尾和浩; 中谷彰洋; 渋谷幸広; 中馬康志; 清原秀泰; 岸本修一; 福島昭二; 砂川 洵
第1２回次世代アジュバント研究会, 2019年01月22日, 英語, ポスター発表
2019年01月22日 - 2019年01月22日 - 天然型BCG-CWS: B-OMS (JBL-107)の研究 3. B-OMS の物理化学的特性／構造
渋谷幸広; 中馬康志; 中谷彰洋; 松尾和浩; 砂川 洵
第1２回次世代アジュバント研究会, 2019年01月22日, 英語, ポスター発表
2019年01月22日 - 2019年01月22日 - 天然型BCG-CWS: B-OMS (JBL-107)の研究 2. B-OMS の製剤
中馬康志; 渋谷幸広; 中谷彰洋; 松尾和浩; 砂川 洵
第1２回次世代アジュバント研究会, 2019年01月22日, 英語, ポスター発表
2019年01月22日 - 2019年01月22日 - 天然型BCG-CWS: B-OMS (JBL-107)の研究 1. B-OMS の調製
中谷彰洋; 渋谷幸広; 中馬康志; 松尾和浩; 砂川 洵
第12回次世代アジュバント研究会, 2019年01月22日, 英語, ポスター発表
2019年01月22日 - 2019年01月22日
